Recently, the whispers surrounding Tesla's potential acquisition of a 10,000-unit order for 'Optimus 3+' robots have taken an unexpected twist. On September 15 (local time), Bright Green, a company listed on the U.S. Pink Sheets—a platform often associated with speculative and low-priced stocks—revealed its merger with PharmAGRI Capital Partners, a firm specializing in pharmaceutical infrastructure. As part of this restructuring, major shareholder Lynn Stockwell was appointed as the chairman and CEO of the newly formed PharmAGRI entity.

The merger announcement highlighted that PharmAGRI had entered into a letter of intent with Tesla, outlining plans to deploy up to 10,000 Optimus 3+ robots across its self-operated farms, active pharmaceutical ingredient synthesis facilities, and prescription drug production lines. The goal, as stated, was to automate and eliminate low-paid, repetitive tasks. However, this claim has been met with skepticism for several reasons.

Firstly, the progress of Tesla's Optimus project has been notably sluggish. To date, only version 2.5 has been released, with the third generation still in the pipeline and far from completion. Challenges in designing the robot's hands have specifically contributed to delays in meeting production targets.

Secondly, Bright Green's financial standing raises red flags. With a market capitalization of merely around $7 million and having filed for bankruptcy protection in February of this year, questions linger about its capacity to secure such a substantial order from Tesla.

Moreover, social media users have pointed out the rudimentary nature of PharmAGRI's webpage, further fueling doubts about the legitimacy of the announcement.

In response to the swirling rumors, Musk simply commented 'fake' under a related social media post. Despite this, neither Bright Green nor Tesla has issued any further statements or clarifications regarding the matter, leaving the public to wonder about the true nature of these alleged transactions.